Frontiers in Psychiatry · 2022 · 25 citations · 22 references
MedicinePharmacologyPsychiatryClinical PharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntidepressant TherapyAnxiety DisordersAnxiety ManagementDepression PharmacotherapyTreatment-resistant Psychiatric DisordersGeneralized Anxiety Disorder AssessmentGeneralized Anxiety Disorder TreatmentGeneralized Anxiety SymptomsKetamine PharmacologyKetamine TherapyKetamine TreatmentTreatment Of Anxiety DisordersTreatment-resistant Anxiety Disorders
Intravenous and intranasal ketamine have been shown to be effective therapeutic options in patients suffering from treatment-resistant depression (TRD). The use of sublingual (SL), rapid dissolve ketamine tablets (RDT) offers a novel approach for delivery for mental health indications. This study assessed the effectiveness and safety of self-administration of off-label, SL, rapid dissolve ketamine tablets (RDT) at-home for depression and anxiety. Intake scores on the Generalized Anxiety Disorder Screener (GAD-7) and Patient Health Questionnaire (PHQ-9) were compared to scores after treatments of three doses of ketamine RDT, and after six doses of ketamine RDT. After three doses of SL ketamine, 47.6% of patients showed a significant decrease in PHQ-9 scores, and 47.6% of patients showed a significant reduction in GAD-7 scores. Reduction rates were higher in those patients who completed a clinically recommended six doses of RDT ketamine. This study demonstrates that SL ketamine is a novel, safe, and effective treatment for TRD and treatment-resistant anxiety. SL ketamine offers an alternative therapeutic approach to IV ketamine when treating those with TRD.
22
Antidepressant effects of ketamine in depressed patients
Robert Berman, Angela Cappiello, Amit Anand et al. · Biological Psychiatry · 2000 · 3.8K citations
Medicine, Pharmacology, Psychiatry +14